LOG IN
SIGN UP
MARKET
TNXP
TNXP
Tonix Pharmaceut
NASDAQ
Real-time Quotes | Nasdaq Last Sale
2.240
+0.180
+8.74%
After Hours: 2.230 -0.01 -0.45% 19:59 05/27 EDT
OPEN
2.050
PREV CLOSE
2.060
HIGH
2.309
LOW
1.980
VOLUME
2.66M
TURNOVER
0
52 WEEK HIGH
45.44
52 WEEK LOW
1.910
MARKET CAP
41.98M
P/E (TTM)
-0.2946
1D
5D
1M
3M
1Y
5Y
Co-Diagnostics extends gains on monkeypox test development
The shares of Co-Diagnostics (NASDAQ:CODX) are trading higher for the third straight session on Friday in solidarity with makers of monkeypox vaccines and therapeutics after molecular diagnostics company announced its
Seekingalpha · 1d ago
New to The Street TV / Newsmax TV announces its 348th Episode with Seven Interviews on This Week’s TV Broadcast, Airing May 29, 2022, 10-11 AM ET
New to The Street TV / Newsmax TV announces its 348th Episode with Seven Interviews on This Week’s TV Broadcast, Airing May 29, 2022, 10-11 AM ET New to The Street’s 348th TV episode line-up features:1). Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) ...
GlobeNewswire · 1d ago
7 Monkeypox Stocks to Watch Right Now
Investor Place · 4d ago
Monkeypox cases rise prompting vaccinations in U.S., Britain, and Germany
Countries from the U.S. to Germany are planning to offer monkeypox vaccinations as the rare viral disease continues to spread outside Central and West Africa, where it is usually detected.
Seekingalpha · 4d ago
GeoVax, Entasis top healthcare gainers, while Nymox, Evoke Pharma lead losers' pack
Gainers: GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Allarity Therapeutics (ALLR) +14%. Tonix Pharmaceuticals (TNXP) +13%. TRxADE HEALTH (MEDS) +13%. Losers: Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%. NanoViricides (NNVC) -19%. Brig...
Seekingalpha · 5d ago
SIGA, Emergent extend gains as monkeypox cases rise
As monkeypox cases continue to rise worldwide, a group of companies focused on therapeutics and vaccines targeted at a close relative of the virus has extended their recent gains in
Seekingalpha · 5d ago
24 Stocks Moving in Monday's Pre-Market Session
Gainers Genocea Biosciences, Inc. (NASDAQ: GNCA) shares rose 33.8% to $0.2795 in pre-market trading after declining around 5% on Friday.
Benzinga · 5d ago
66 Biggest Movers From Friday
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.
Benzinga · 6d ago
No Data
Learn about the latest financial forecast of TNXP. Analyze the recent business situations of Tonix Pharmaceut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 2 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TNXP stock price target is 54.40 with a high estimate of 96.00 and a low estimate of 19.20.
Current 2.240
EPS
Actual
Estimate
-1.28-0.96-0.64-0.32
Institutional Holdings
Institutions: 100
Institutional Holdings: 123.21M
% Owned: 657.45%
Shares Outstanding: 18.74M
TypeInstitutionsShares
Increased
8
606.79K
New
5
58.66K
Decreased
6
42.07K
Sold Out
5
39.10K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Chief Executive Officer/President/Director
Seth Lederman
Chief Financial Officer/Treasurer
Bradley Saenger
Chief Operating Officer
Jessica Morris
Secretary
Gregory Sullivan
Lead Director/Independent Director
James Treco
Independent Director
Richard Bagger
Independent Director
Margaret Bell
Independent Director
David Grange
Independent Director
Adeoye Olukotun
Independent Director
Carolyn Taylor
No Data
No Data
About TNXP
Tonix Pharmaceuticals Holding Corp. (Tonix) is a clinical-stage biopharmaceutical company. The Company is focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonixs portfolio is primarily composed of immunology and central nervous system (CNS) product candidates. Tonixs immunology portfolio includes a COVID-19 platform of product candidates to prevent and treat COVID-19, to treat Long COVID as well as to detect functional T cell immunity to COVID-19. Tonixs lead vaccine candidate for COVID-19, TNX-18001, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. The Company's CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonixs lead CNS candidate, TNX-102 SL3, is in mid-Phase III development for the management of fibromyalgia.
Webull offers kinds of Tonix Pharmaceuticals Holding Corp stock information, including NASDAQ:TNXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNXP stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading TNXP stock methods without spending real money on the virtual paper trading platform.